{"doi":"10.1016/j.jcf.2024.11.001","title":"Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis","abstract":null,"journal":"Journal of Cystic Fibrosis","year":2025,"id":641293,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":700945,"name":"Nicholas J. Simmonds","orcid":"0000-0002-1705-4780","position":1,"is_corresponding":false},{"id":1667249,"name":"Silke van-Koningsbruggen-Rietschel","orcid":null,"position":2,"is_corresponding":false},{"id":1667250,"name":"Jutta Bend","orcid":"0000-0002-1230-2650","position":3,"is_corresponding":false},{"id":1667251,"name":"Fiona Dunlevy","orcid":"0000-0002-2339-1257","position":4,"is_corresponding":false},{"id":1390768,"name":"K. Hill","orcid":"0000-0001-5561-8893","position":5,"is_corresponding":false},{"id":390095,"name":"Lieven Dupont","orcid":"0000-0003-3961-1522","position":6,"is_corresponding":false},{"id":486164,"name":"D.G. Downey","orcid":"0000-0002-6471-549X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis","abstract":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy has transformed the lives of many people with CF (pwCF) with improved quality of life (QoL), fewer pulmonary exacerbations (PEx) and hospitalisations, and slower decline in pulmonary function [1]. However, many pwCF still lack effective disease modifying therapy. For example, the European Medicines Agency has authorised the triple combination modulator treatment, elexacaftor-tezacaftor-ivacaftor (ETI) in pwCF (aged 2 years and above) who have at least one F508del mutation.","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39581782","pmcid":null,"openalex_id":"https://openalex.org/W4404643204","authors":[],"funders":[],"total_grants":0,"fwci":0.6747,"citation_percentile":0.74043423,"influential_citations":0,"citation_trend":[{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://www.cysticfibrosisjournal.com/article/S1569-1993(24)01809-5/pdf","host_type":"journal"},{"url":"https://www.cysticfibrosisjournal.com/article/S1569-1993(24)01809-5/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1569199324018095?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1569199324018095?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jcf.2024.11.001","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39581782","host_type":"repository"},{"url":"https://pure.qub.ac.uk/en/publications/aff4aaca-fc84-4170-a7ff-125a1df28b7d","host_type":"repository"},{"url":"https://lirias.kuleuven.be/handle/20.500.12942/767543","host_type":"repository"},{"url":"https://lirias.kuleuven.be/retrieve/ed32e611-766d-4a77-85a5-c790fa893d8c","host_type":"repository"}],"fields_of_study":["Cystic Fibrosis Research Advances","Tracheal and airway disorders","Neonatal Respiratory Health Research"],"mesh_terms":[],"keywords":["Cystic fibrosis","Medicine","Bridging (networking)","Intensive care medicine","Clinical trial","Lung","Lung infection","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T17:06:04.359723Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}